Home > Boards > US Listed > Medical - Drugs > AVEO Pharmaceuticals, Inc. (AVEO)

Sir, with all due respect in regards to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
harry crumb Member Profile
 
Followed By 178
Posts 9,247
Boards Moderated 0
Alias Born 03/15/13
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 7:16:33 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2019 7:15:55 AM
AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire - 11/12/2019 7:00:00 AM
AVEO Oncology & Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination w... Business Wire - 11/7/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 7:02:44 AM
AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma Business Wire - 11/4/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/3/2019 9:12:29 AM
AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (... Business Wire - 9/30/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2019 7:24:47 AM
AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Business Wire - 9/26/2019 7:00:00 AM
AVEO Oncology & EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell... Business Wire - 9/23/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/17/2019 5:23:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 4:11:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2019 9:44:00 AM
AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carc... Business Wire - 9/10/2019 6:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2019 5:26:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/8/2019 7:06:22 AM
AVEO Reports Second Quarter 2019 Financial Results and Provides Business Update Business Wire - 8/8/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 6:16:14 AM
Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology Business Wire - 8/1/2019 6:00:00 AM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 6/14/2019 8:03:55 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 5:02:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 5:01:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 5:01:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/13/2019 4:07:06 PM
harry crumb   Saturday, 09/28/19 09:28:07 AM
Re: None
Post # of 5066 
Sir, with all due respect in regards to you an the many others suffering from this terrible disease, nothing of any more importance would be a true cure to halt this desease. Unfortunately aveo’s drug will not meet the demands of the fda in my opinion, as it has already failed prior testing, if it truly worked so well it would have been fast tracked already an big pharma would be all over it. Neither of the above has happened, nor will it. Theres no big investors with their foot in the door as is what happens with any new drug. The share price cant even hold 1$, thats sad, an thats the hint everyone needs to be aware of. Theres no insider buying either, the cfo quit, another hint to consider. These are all facts not fiction.This in my opinion is nothing close to a miracle drug that the fda will approve. Best of luck to you, be strong my friend.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist